Sign In
Learn bits
Health & Medicine
Mahesh

15/07/24 12:30 PM IST

India could soon allow ‘game-changing’ weight-loss drug tirzepatide

In News
  • Last week, in a first, an expert committee of India’s drug regulator gave the green light to the drug tirzepatide. 
Diabetes drug
  • In 2017, the US Food and Drugs Administration (FDA) approved Danish pharma giant Novo Nordisk’s Ozempic, with the active ingredient semaglutide, to manage type 2 diabetes. Soon, doctors in the US saw an interesting side-effect — weight loss.
  • They started prescribing Ozempic off-label (the practice of prescribing a drug for a different purpose than what has been approved) to treat obesity.
  • This made Novo Nordisk explore semaglutide as a weight loss drug for people without diabetes. In 2021, the company released Wegovy, a semaglutide injection, as an FDA-approved obesity treatment. The key difference between Ozempic and Wegovy: the maximum approved dose of semaglutide is slightly higher with Wegovy than Ozempic.
  • Currently, there is a global shortage of both drugs amid soaring demand.
Semaglutide vs tirzepatide
  • The FDA has approved Wegovy (semaglutide) and Zepbound (tirzepatide) for chronic weight management in adults.
  • These drugs can be prescribed to those who are obese (with a body mass index of over 30), or overweight (with a BMI between 27 and 30), and have at least one other health condition related to their weight (such as high blood pressure, high cholesterol, or type 2 diabetes).
  • Both are administered as under-the-skin injections, and are intended to be used alongside a reduced-calorie diet and increased physical activity.
  • The dosage is increased gradually, reaching a maximum dosage of 2.4 mg for semaglutide and 15 mg for tirzepatide.
  • This does not, however, mean that the latter is ‘stronger’ than the former.
  • Semaglutide and tirzepatide are polypeptides, small proteins that boost the levels of naturally-occurring hormones in the body, including that of glucagon-like-peptide 1 (GLP-1), which control weight through the brain and digestive tract.
  • Higher GLP-1 levels, released in the gut, spark a reaction by stimulating neurons that alter gut function, leading to a sense of fullness.
  • This process also taps into a brain mechanism that lights up neural pathways, triggering the sensation of satiety — the feeling of being satisfied and having had enough to eat.
  • They also help manage glucose levels, making them an effective treatment for diabetes.
  • Semaglutide only targets GLP-1 receptors. On the other hand, tirzepatide also boosts a second hormone: glucose-dependent insulinotropic polypeptide (GIP).
  • The GIP also regulates weight through receptors in brain and fat cells. Eli Lilly claims that the combined action of GLP-1 and GIP enhance each other’s effects.
Side effects of the drug
  • According to the company, Zepbound’s most common side effects include nausea, diarrhoea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, allergic reactions, belching, hair loss, and heartburn.
  • Eli Lilly specifically highlights the risk of thyroid tumours, including thyroid cancer.
  • The possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath.
  • Individuals cannot use Zepbound if they, or any family members, have ever had medullary thyroid carcinoma (MTC), a type of thyroid cancer, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a rare, inherited disorder that affects the endocrine glands.
  • Zepbound is a prescription medicine. It cannot — and should not — be used for cosmetic weight loss
  • Improvements in heart and metabolic health seen during the treatment period also tended to revert to baseline levels once the treatment was stopped.
Source- Indian Express

More Related Current Affairs View All

20 Sep

Cabinet clears setting up of National Centre of Excellence in Mumbai for Animation, Visual Effects, Gaming, Comics and Extended Reality

'The Government has recently said that the Animation, Visual Effects, Gaming and Comic (AVGC) sector has the potential to provide employment to over 20 lakh people in the coming 10

Read More

20 Sep

Mini-moon

'According to a new study, the Earth’s gravitational field will temporarily capture a small asteroid, called 2024 PT5, in late September.' The asteroid will stay for two m

Read More

19 Sep

Cabinet clears development of Next Generation of satellite Launch Vehicle

'The Union Cabinet, led by Prime Minister Narendra Modi, has approved the development of the Next Generation Launch Vehicle (NGLV).' The NGLV is set to significantly enhance Ind

Read More

India’s First Ai-Driven Magazine Generator

Generate Your Custom Current Affairs Magazine using our AI in just 3 steps